anti angiogenic Drugs - Cancer Science

What are Anti-Angiogenic Drugs?

Anti-angiogenic drugs are a class of medications designed to inhibit the formation of new blood vessels. This process, known as angiogenesis, is a critical mechanism that tumors exploit to supply themselves with the oxygen and nutrients needed for growth and metastasis.

How Do These Drugs Work?

Anti-angiogenic drugs work by targeting specific pathways and molecules involved in angiogenesis. The most common targets include Vascular Endothelial Growth Factor (VEGF) and its receptors. By blocking these pathways, the drugs can effectively starve the tumor, limiting its ability to grow and spread.

Common Anti-Angiogenic Drugs

Several anti-angiogenic agents have been approved for clinical use. Among the most well-known are Bevacizumab (Avastin), Sunitinib (Sutent), and Sorafenib (Nexavar). Each of these drugs has specific mechanisms of action and is used to treat various types of cancers.

Indications and Uses

Anti-angiogenic drugs are used in the treatment of several cancers, including colorectal cancer, renal cell carcinoma, and glioblastoma. Their application depends on the type and stage of cancer, as well as the overall health of the patient.

Side Effects and Risks

While anti-angiogenic drugs can be effective, they also come with potential side effects. Common adverse effects include hypertension, proteinuria, and gastrointestinal perforations. Long-term use can lead to more severe complications, necessitating careful monitoring by healthcare providers.

Advantages Over Traditional Chemotherapy

Unlike traditional chemotherapy, which targets rapidly dividing cells, anti-angiogenic drugs specifically target the tumor's blood supply. This can result in fewer side effects and a different toxicity profile. Additionally, they can be combined with other treatments to enhance efficacy.

Limitations and Challenges

Despite their promise, anti-angiogenic drugs are not without limitations. Tumors can develop resistance, and the effectiveness of these drugs can diminish over time. Research is ongoing to understand and overcome these resistance mechanisms.

Future Directions

The field of anti-angiogenic therapy is rapidly evolving. Newer agents and combination therapies are being investigated to improve outcomes. Advances in personalized medicine also hold the potential to tailor anti-angiogenic treatments to individual patients, maximizing efficacy while minimizing side effects.

Relevant Publications

Ornidazole Inhibits the Angiogenesis and Migration Abilities of Non-small Cell Lung.

Issue Release: 2024

Deciphering hepatoma cell resistance to tyrosine kinase inhibitors: insights from a Liver-on-a-Chip model unveiling tumor endothelial cell mechanisms.

Issue Release: 2024

Anti-angiogenic and antioxidant effects of axitinib in human retinal endothelial cells: implications in diabetic retinopathy.

Issue Release: 2024

Bergenin inhibits growth of human cervical cancer cells by decreasing Galectin-3 and MMP-9 expression.

Issue Release: 2024

A Comprehensive Review of the Efficacy and Safety of Dopamine Agonists for Women with Endometriosis-associated Infertility from Inception to July 31, 2022.

Issue Release: 2024

Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.

Issue Release: 2024

Novel bibenzyl compound Ae exhibits anti-agiogenic activity in HUVECs in vitro and zebrafish in vivo.

Issue Release: 2024

Hyaluronidase improves the efficacy of nab-paclitaxel after prolonged angiogenesis inhibition in preclinical models for esophagogastric cancer.

Issue Release: 2024

Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report.

Issue Release: 2024

A case of surgically treated non-metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report and literature review.

Issue Release: 2024

Construction of ROS-Responsive Hyaluronic Acid Modified Paclitaxel and Diosgenin Liposomes and Study on Synergistic Enhancement of Anti-Ovarian Cancer Efficacy.

Issue Release: 2024

Available Therapeutic Options for Corneal Neovascularization: A Review.

Issue Release: 2024

Cyclopeptide moroidin inhibits vasculogenic mimicry formed by glioblastoma cells regulating β-catenin activation and EMT pathways.

Issue Release: 2024

[Application of optical coherence tomography in the assessment of the posterior lens capsule during anti-angiogenic therapy].

Issue Release: 2024

Arsenic Trioxide Suppresses Angiogenesis in Non-small Cell Lung Cancer via the Nrf2-IL-33 Signaling Pathway.

Issue Release: 2024

Hepatic manifestations of hereditary haemorrhagic telangiectasia.

Issue Release: 2024

A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma.

Issue Release: 2024

Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment.

Issue Release: 2024

Therapeutic Potential of Natural Compounds from Herbs and Nutraceuticals in Alleviating Neurological Disorders: Targeting the Wnt Signaling Pathway.

Issue Release: 2024

Nature\'s Elixir for Cancer Treatment: Targeting Tumor-induced Neovascularization.

Issue Release: 2024

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Partnered Content Networks

Relevant Topics